Table 3.
Adjusteda HR (95% CI) for log-transformed hs-troponin (per 1 SD) with all-cause mortality with and without mutual adjustment for the other hs-troponin assays
| Roche hs-troponin T | Abbott hs-troponin I | Siemens hs-troponin I | Ortho hs-troponin I | |
|---|---|---|---|---|
| hazard ratio (95% CI) | hazard ratio (95% CI) | hazard ratio (95% CI) | hazard ratio (95% CI) | |
| All-cause mortality | ||||
| Model 1 | 1.46 (1.35–1.58) | 1.29 (1.23–1.36) | 1.18 (1.10–1.27) | 1.31 (1.22–1.42) |
| Model 2 | 1.31 (1.21–1.42) | 1.20 (1.13–1.28) | 1.10 (1.02–1.18) | 1.23 (1.14–1.32) |
| Model 2 plus Roche hs-troponin Tb | - | 1.10 (1.01–1.19) | 0.99 (0.92–1.06) | 1.11 (1.02–1.20) |
| Model 2 plus Abbott hs-troponin Ib | 1.25 (1.14–1.38) | - | 0.94 (0.84–1.05) | 1.12 (1.02–1.22) |
| Model 2 plus Siemens hs-troponin Ib | 1.31 (1.21–1.42) | 1.24 (1.12–1.37) | - | 1.22 (1.12–1.32) |
| Model 2 plus Ortho hs-troponin Ib | 1.27 (1.16–1.38) | 1.15 (1.06–1.24) | 1.02 (0.94–1.10) | - |
| CVD mortality | ||||
| Model 1 | 1.77 (1.53–2.04) | 1.60 (1.41–1.81) | 1.66 (1.23–2.24) | 1.91 (1.48–2.47) |
| Model 2 | 1.49 (1.28–1.75) | 1.44 (1.26–1.66) | 1.45 (1.06–1.97) | 1.65 (1.23–2.22) |
| Model 2 plus Roche hs-troponin Tb | - | 1.28 (1.11–1.47) | 1.20 (0.91–1.58) | 1.39 (1.03–1.88) |
| Model 2 plus Abbott hs-troponin Ib | 1.30 (1.11–1.52) | - | 0.98 (0.71–1.36) | 1.29 (0.94–1.78) |
| Model 2 plus Siemens hs-troponin Ib | 1.41 (1.22–1.64) | 1.46 (1.19–1.79) | - | 1.52 (1.11–2.07) |
| Model 2 plus Ortho hs-troponin Ib | 1.35 (1.13–1.60) | 1.29 (1.09–1.53) | 1.19 (0.87–1.63) | - |
CVD, cardiovascular disease; SD, standard deviation; eGFR, estimated glomerular filtration ratio.
Model 1: association of each hs-troponin assay (Columns 2–5) with events after adjusting for age, sex, race/ethnicity. Model 2: adjusted for age, sex, race/ethnicity, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, cigarette smoking status, diabetes mellitus, family history of CVD, body mass index, use of blood pressure medications, use of cholesterol-lowering medications, and eGFR.
These models report the association of each hs-troponin exposure with mortality, after adjustment for the variables in Model 2 and further adjustment for concentrations from one other hs-troponin assay (i.e. these models contain two hs-troponin assays).